Janux Therapeutics annual operating margin
2021
2022
2023
2024
2025
Janux Therapeutics's operating margin was −1,576.67% for fiscal 2025.
View full Janux Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,576.67% | −643.09 pp |
| 2024 | 2024-12-31 | −933.58% | −30.71 pp |
| 2023 | 2023-12-31 | −902.87% | −123.83 pp |
| 2022 | 2022-12-31 | −779.04% | +126.35 pp |
| 2021 | 2021-12-31 | −905.39% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −308.66% | −153.30 pp |
| Q1 2026 | 2026-03-31 | −916.50% | +693.80 pp |
| Q3 2025 | 2025-09-30 | −352.51% | +303.20 pp |
| Q3 2024 | 2024-09-30 | −8,164.46% | −7536.22 pp |
| Q2 2024 | 2024-06-30 | −155.36% | +1807.56 pp |
| Q1 2024 | 2024-03-31 | −1,610.30% | −620.02 pp |
| Q4 2023 | 2023-12-31 | −655.71% | −13.67 pp |
| Q3 2023 | 2023-09-30 | −628.25% | +365.80 pp |
| Q2 2023 | 2023-06-30 | −1,962.91% | −1233.06 pp |
| Q1 2023 | 2023-03-31 | −990.28% | −138.05 pp |
| Q4 2022 | 2022-12-31 | −642.04% | +192.74 pp |
| Q3 2022 | 2022-09-30 | −994.04% | −53.32 pp |
| Q2 2022 | 2022-06-30 | −729.85% | +567.24 pp |
| Q1 2022 | 2022-03-31 | −852.23% | −251.18 pp |
| Q4 2021 | 2021-12-31 | −834.78% | — |
| Q3 2021 | 2021-09-30 | −940.72% | — |
| Q2 2021 | 2021-06-30 | −1,297.10% | — |
| Q1 2021 | 2021-03-31 | −601.05% | — |
Across the available reported history, Janux Therapeutics's operating margin decreased from −933.58% to −1,576.67%, a change of −643.09 percentage points. The latest reported quarter, Q2 2026, shows −308.66%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Janux Therapeutics filings at SEC.gov ↗